Cover Image
市場調查報告書

異生性大細胞淋巴瘤(ALCL):開發平台分析

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 257813
出版日期 內容資訊 英文 104 Pages
訂單完成後即時交付
價格
Back to Top
異生性大細胞淋巴瘤(ALCL):開發平台分析 Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 104 Pages
簡介

異生性大細胞淋巴瘤(ALCL)是罕見的非何杰金氏淋巴瘤。這些癌細胞積存在淋巴結中。此外也會在皮膚及肺等身體其他部位產生。常見的症狀有頸椎·腋下·鼠蹊部的無痛性腫脹、咳嗽和呼吸急促、盜汗、高溫和體重減少、食慾不振、疲勞等。治療方法包含化療,放射線治療等。

本報告提供異生性大細胞淋巴瘤(ALCL)治療藥的開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

異生性大細胞淋巴瘤(ALCL)概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

開發治療藥的企業

  • Akron Molecules AG
  • AstraZeneca Plc
  • Bayer AG
  • Celon Pharma Sp. z o.o.
  • Pfizer Inc.
  • Sareum Holdings Plc
  • Seattle Genetics, Inc.
  • Teva Pharmaceutical Industries Limited

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • AdIL-24
  • AKR-302
  • AKR-303
  • AZD-3463
  • brentuximab vedotin
  • CEP-28122
  • CEP-37440
  • copanlisib hydrochloride
  • crizotinib
  • Drug to Inhibit ALK for Anaplastic Large Cell Lymphoma
  • KRA-0008
  • SH-7129
  • Small Molecules to Inhibit Aurora and ALK Kinase for Oncology
  • Small Molecules to Inhibit Aurora Kinase and FLT3 Kinase for Oncology

開發中產品的最新趨勢

暫停的計劃

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8288IDB

Summary

Global Markets Direct's, 'Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H2 2016', provides an overview of the Anaplastic Large Cell Lymphoma (ALCL) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anaplastic Large Cell Lymphoma (ALCL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anaplastic Large Cell Lymphoma (ALCL) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Anaplastic Large Cell Lymphoma (ALCL)
  • The report reviews pipeline therapeutics for Anaplastic Large Cell Lymphoma (ALCL) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Anaplastic Large Cell Lymphoma (ALCL) therapeutics and enlists all their major and minor projects
  • The report assesses Anaplastic Large Cell Lymphoma (ALCL) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Anaplastic Large Cell Lymphoma (ALCL)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Anaplastic Large Cell Lymphoma (ALCL)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Anaplastic Large Cell Lymphoma (ALCL) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Anaplastic Large Cell Lymphoma (ALCL) Overview
  • Therapeutics Development
    • Pipeline Products for Anaplastic Large Cell Lymphoma (ALCL) - Overview
  • Anaplastic Large Cell Lymphoma (ALCL) - Therapeutics under Development by Companies
  • Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Anaplastic Large Cell Lymphoma (ALCL) - Products under Development by Companies
  • Anaplastic Large Cell Lymphoma (ALCL) - Companies Involved in Therapeutics Development
    • Ariad Pharmaceuticals, Inc.
    • AstraZeneca Plc
    • Bayer AG
    • Celon Pharma Sp. z o.o.
    • Pfizer Inc.
    • Sareum Holdings Plc
    • Seattle Genetics, Inc.
    • Teva Pharmaceutical Industries Ltd.
  • Anaplastic Large Cell Lymphoma (ALCL) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AdIL-24 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AZD-3463 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • brentuximab vedotin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • brigatinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CEP-37440 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • copanlisib hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • crizotinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug to Inhibit ALK for Anaplastic Large Cell Lymphoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAR-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAR-4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SH-7129 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Anaplastic Large Cell Lymphoma (ALCL) - Dormant Projects
  • Anaplastic Large Cell Lymphoma (ALCL) - Discontinued Products
  • Anaplastic Large Cell Lymphoma (ALCL) - Product Development Milestones
    • Featured News & Press Releases
      • Jan 22, 2016: European Commission Approves Label Variation for ADCETRIS to Include Data on Retreatment of Adult Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma
      • Jun 17, 2015: Seattle Genetics Announces Multiple ADCETRIS (Brentuximab Vedotin) Data Presentations at the International Conference on Malignant Lymphoma
      • Dec 07, 2014: Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting
      • Dec 06, 2014: Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting
      • Nov 07, 2014: Seattle Genetics to Present Clinical Data from Broad ADCETRIS (Brentuximab Vedotin) Development Program and Novel Antibody-Drug Conjugates at ASH 2014
      • Nov 06, 2014: Takeda Announces Abstracts for ADCETRIS (brentuximab vedotin) in Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma to be Presented at 56th American Society of Hematology Annual Meeting
      • Sep 24, 2014: Seattle Genetics Highlights Updated Progression-Free Survival and Overall Survival Data from ADCETRIS (Brentuximab Vedotin) Frontline PTCL Phase 1 Clinical Trial at the ESMO 2014 Congress
      • Apr 17, 2014: ADCETRIS 50mg for intravenous drip infusion", Treatment for Patients with CD30 Positive Relapsed or Refractory Hodgkin Lymphoma or Relapsed or Refractory Anaplastic Large Cell Lymphoma Now Available in Japan
      • Jan 17, 2014: Seattle Genetics Announces ADCETRIS Approval in Japan for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma
      • Jun 21, 2013: Seattle Genetics Highlights Adcetris Clinical Data At International Conference On Malignant Lymphoma
      • Jun 19, 2013: Takeda And Seattle Genetics Highlight Post-Hoc Analysis Examining Progression-free Survival With Adcetris At International Conference On Malignant Lymphoma
      • Jun 01, 2013: Takeda Highlights Data From Phase I/II Clinical Trial Examining Use Of Adcetris in Pediatric Patients With Hodgkin Lymphoma Or Systemic Anaplastic Large Cell Lymphoma
      • May 14, 2013: Seattle Genetics Announces Adcetris Supplemental BLA Accepted For Filing By FDA
      • Mar 22, 2013: Takeda Submits New Drug Application For Brentuximab Vedotin In Japan
      • Mar 18, 2013: Seattle Genetics Submits Supplemental BLA To FDA For Retreatment And Extended Duration Of Therapy With Adcetris In Relapsed Hodgkin Lymphoma And Systemic ALCL
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Anaplastic Large Cell Lymphoma (ALCL), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Ariad Pharmaceuticals, Inc., H2 2016
  • Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by AstraZeneca Plc, H2 2016
  • Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Bayer AG, H2 2016
  • Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Celon Pharma Sp. z o.o., H2 2016
  • Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Pfizer Inc., H2 2016
  • Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Sareum Holdings Plc, H2 2016
  • Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Seattle Genetics, Inc., H2 2016
  • Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Anaplastic Large Cell Lymphoma (ALCL) - Dormant Projects, H2 2016
  • Anaplastic Large Cell Lymphoma (ALCL) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Anaplastic Large Cell Lymphoma (ALCL), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top